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Methods: The correlation between antimicrobial agent consumption and related resistance in
the Gram-negative bacteria Acinetobacter baumannii, Escherichia coli, Klebsiella pneumo-
niae, Pseudomonas aeruginosa, and Proteus mirabilis was analyzed during the period 2003
e2011.
Results: Among these five bacteria, overall E. coli and K. pneumoniae were more commonly
isolated from bloodstream than the other species. Regarding Enterobacteriaceae, E. coli
and K. pneumoniae showed annual increases of resistance to the tested antimicrobial agents;
conversely, P. mirabilis exhibited reduced resistance to cefuroxime, ceftriaxone and cefe-
pime. In contrast to the relatively low antimicrobial resistance in P. aeruginosa, A. baumannii
revealed high resistance, which was over 85% resistant rate to the tested antimicrobial agents
and over 80% carbapenem resistance in 2011. E. coli, K. pneumoniae, and P. mirabilis differed
in development of antimicrobial resistance after consumption of the antimicrobial agents.
K. pneumoniae developed resistance to all antimicrobial groups, whereas resistance in
P. mirabilis was not related to any antimicrobial consumption. P. aeruginosa developed
resistance to b-lactam antimicrobials and aminoglycosides, whereas A. baumanii developed
resistance to carbapenems after their use.of Microbiology, Immunology, and Pharmaceuticals, National Chiayi University, 300 University Road,
du.tw (C. Chu).
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Extended-spectrum cephalosporins, b-lactam with b-lacta-
mase inhibitor, carbapenems, fluoroquinolones, and ami-
noglycosides are common antimicrobial agents used in the
treatment of bacterial infections. However, application of
these antimicrobial agents can induce antimicrobial resis-
tance through mutations and the transfer of mobile ele-
ments harboring resistance genes, thus increasing the
incidence of drug-resistant bacteria. Some examples
include extended-spectrum b-lactamase (ESBL)-producing
bacteria carrying bla genes for cephalosporin resistance1,2
and fluoroquinolone-resistant bacteria with mutations in
topoisomerases II and IV and altered expression of efflux
pumps.3,4
The emergence of multidrug resistant (MDR) bacteria
not only causes public health problems but also increases
medical costs and the hospitalization, morbidity and mor-
tality of patients.5 MDR Gram-negative bacteria are major
nosocomial pathogens and are increasing annually
worldwide6e11 and in Taiwan12,13; these species include
ESBL-producing Klebseiella pneumoniae and Escherichia
coli, MDR Pseudomonas aeruginosa,14,15 and pan-drug
resistant Acinetobacter baumannii.16 Carbapenems have
recently been replaced the extended-spectrum cephalo-
sporins to treat ESBL-producing bacteria; accordingly, car-
bapenem resistance has been observed in P. aeruginosa
(i.e., imipenem)17 and A. baumannii (CRAB).18,19 In Taiwan,
CRAB isolates have increased gradually, with the highest in
central Taiwan.20 In this study, we analyzed the resistance
profile of major Gram-negative bacteria, the consumption
of antimicrobial agents and the correlation between anti-
microbial usage and development of resistance.
Materials and methods
Retrospective study
All information was collected from Chiayi Branch, Taichung
Veterans Hospital from 2003 to 2011. The hospital has 445
beds, including 24 beds for intensive care units, 40 beds for
the respiratory care ward, 250 beds for general in-patients,
and 225 beds for psychiatry patients. The hospital also has a
246-bed nursing home.
Bacterial identification and antimicrobial
susceptibility test
Clinical isolates of A. baumannii, E. coli, K. pneumoniae, P.
aeruginosa, and P. mirabilis were identified using the
Phoenix and VITEK system in the Medical Laboratory Divi-
sion. The antimicrobial susceptibility to the antimicrobialagents was determined according to the guidelines of
Clinical and Laboratory Standards Institute.21 The antimi-
crobial agents analyzed included: amikacin, gentamicin,
and isepamicin (aminoglycosides); cefazolin, cephradine,
and cephalexin (first-generation cephalosporins); flomoxef,
cefuroxime, cefoxitin, ceftazidime, ceftriaxone, and
cefepime (extended-spectrum cephalosporins); imipenem,
meropenem, and ertapenem (carbapenems); ciprofloxacin,
levofloxacin, and moxifloxacin (fluoroquinolones); ampi-
cillin/sulbactam, amoxicillin/clavulanic acid, piperacillin,
piperacillin/tazobactam (penicillins and penicillin with b-
lactamase inhibitor); and tigecycline. The defined daily
dose represents the antimicrobial usage of 1000 patients
and was used for the statistical analysis.
Statistical analysis
Linear regression was performed to determine the corre-
lation coefficient (r) of antimicrobial agent consumption
and antimicrobial resistance of each species associated
with specific years. Furthermore, correlation coefficients of
antimicrobial agent consumption and antimicrobial resis-
tance in each species were calculated, and a t test for was
applied to ascertain significant differences (p < 0.05).
Results
Clinical isolates of five Gram-negative bacteria
The number of clinical isolates differed among the species
with the highest for P. aeruginosa, followed by E. coli, A.
baumannii, K. pneumoniae, and P. mirabilis (Table 1).
Although the clinical isolates of each species differed
annually, maximal number was observed for P. aeruginosa,
E. coli, and K. pneumoniae in 2008 and for P. mirabilis in
2009. A. baumannii clinical isolates increased annually
from 2003 to 2011. These five species differed in preva-
lence of bloodstream isolates from the highest for E. coli
(13.5%), followed by K. pneumoniae (9.8%), A. baumannii
(5.9%), P. mirabilis (5.9%) and P. aeruginosa (3.6%). Inter-
estingly, A. baumannii showed an increase in bloodstream
isolates and mainly were CRAB (88%).
Consumption of antimicrobial agents
The consumption level of five major antimicrobial groups
differed with a gradual reduction in aminoglycosides
(r Z 0.88, p < 0.01) and first-generation cephalosporins
(r Z 0.92, p < 0.01), an annual increase in extended-
spectrum cephalosporins (r Z 0.92, p < 0.01) and carba-
penems (r Z 0.93, p < 0.01), with an exceptional use of
fluoroquinolones and penicillins in 2006 and 2007,
Table 1 Clinical and bloodstream isolates of five prevalent bacterial species from 2003 to 2011
Year Escherichia
coli
Pseudomonas
aeruginosa
Klebsiella
pneumoniae
Acinetobacter
baumannii
Proteus
mirabilis
Total
Total clinical isolates
2003 394 453 152 271 105 1375
2004 459 561 226 268 90 1604
2005 653 748 371 310 224 2306
2006 570 800 458 442 296 2566
2007 497 551 417 416 165 2046
2008 545 638 482 348 218 2231
2009 546 569 445 380 333 2273
2010 527 496 346 396 202 1967
2011 712 620 468 612 320 2732
Total 4903 5436 3365 3443 1953 19,100
Mean 544.8 604 373.9 382.6 217 2122.2
From bloodstream isolates
2003 60 16 15 23 7 121
2004 67 11 18 11 7 114
2005 86 16 45 11 16 174
2006 53 15 40 15 12 135
2007 53 16 29 14 18 130
2008 51 18 44 12 13 138
2009 93 47 30 19 15 204
2010 65 23 38 32 12 170
2011 132 32 70 67 15 316
Total 660 194 329 204 115 1502
Mean 73.3 21.6 36.6 22.7 12.8 166.9
Bloodstream isolate rate (%) 13.5 3.6 9.8 5.9 5.9 7.9
Antimicrobial use and resistance development 649respectively (Table 2). Furthermore, the consumption level
of antimicrobial agents in each group varied. For the ami-
noglycosides, an increase in amikacin and reduction in
gentamicin were observed. With regard to the fluo-
roquinolones, a significant reduction in ciprofloxacin and
increase in levofloxacin were found (p < 0.05). Of penicil-
lins, ampicillin/sulbactam and piperacillin reached the
maximal consumption in 2007 and 2008, respectively, and
then decreased in contrast to the increase in the use of
amoxicillin/clavulanic acid and piperacillin/tazobactam
annually. For the extended-spectrum cephalosporins, a
significant increase in ceftriaxone, cefoxitin, and flomoxef
and decrease in cefuroxime were observed. The consump-
tion level of imipenem and meropenem was decreased
since 2008 and 2009, respectively, while an increase in
ertapenem was observed at the same period.
Antimicrobial susceptibility
The antimicrobial agent selected to treat infections depend
on the bacterial species involved. Therefore, antimicrobial
resistance and its prevalence differed among these five
species (Table 3). Comparing the antimicrobial resistance
of E. coli, K. pneumoniae, and P. mirabilis of Enter-
obacteriaceae, E. coli showed significant increase in the
resistance (over 40%; r > 0.9, p < 0.05) to ampicillin/sul-
bactam, cefazolin, cefoxitin, ceftazidime, and ceftriaxone
of the b-lactam antimicrobials, and to ciprofloxacin and
levofloxacin of the fluoroquinolones. In contrast, the
average resistance rate (20%) was for cefepime,meropenem, and piperacillin/tazobactam. All K. pneumo-
niae isolates exhibited significantly increased resistance
(r > 0.70, p < 0.05) to all antimicrobial agents, except
gentamicin, cefepime, levofloxacin, and meropenem.
These two species differed in the antimicrobial resistance
rate. Higher resistance rates were observed in E. coli for
ampicillin/sulbactam, ceftriaxone, ciprofloxacin and levo-
floxacin and in K. pneumoniae for cefepime, meropenem
and piperacillin/tazobactam. In contrast to the above two
species, P. mirabilis displayed annual increases in resis-
tance only to amikacin (r Z 0.70, p < 0.05).
In P. aeruginosa, resistance rate was increased in cef-
tazidime, piperacillin/tazobactam, and carbapenems of
meropenem (p Z 0.03) and imipenem (p Z 0.08), but
reduced in aminoglycosides (r < 0.8, p < 0.05). All A.
baumannii isolates showed the highest resistance rate to all
antimicrobials examined, particularly ampicillin/sulbac-
tam, meropenem, ciprofloxacin, and levofloxacin, with
nearly 90% in recent years. However, an annual increase in
resistance was only found to be significant for imipenem
and meropenem (r > 0.9, p < 0.05), ciprofloxacin
(r Z 0.96, p < 0.001) and ampicillin/sulbactam (r Z 0.95,
p < 0.001).
Association of antimicrobial resistance rate and
antimicrobial dosage
Although 26 antimicrobial agents and five bacterial species
were investigated, a significant correlation between the
antimicrobial resistance rate of six antimicrobial agent
Table 2 Annual consumption of antimicrobial agents from 2003 to 2011
Antimicrobial agents Antibiotic consumption (DDD/1000 patient-days) by yeara
2003 2004 2005 2006 2007 2008 2009 2010 2011 Mean r p
Aminoglycosides 68.9 73.7 54.3 44.1 46.4 43.9 32.6 32.8 40.0 48.5 0.88 0.00
Amikacin 4.0 4.7 3.9 4.7 7.5 11.6 11.2 11.6 12.7 8.0 0.96 0.00
Gentamicin 65.0 69.0 50.7 39.4 38.9 32.2 21.3 21.2 25.6 40.4 0.94 0.00
First-generation cephalosporins 172 189 165 132 135 128 105 110 112 139 0.92 0.00
Extended-spectrum cephalosporins 29.2 26.9 48.3 61.1 40.6 68.0 67.6 72.4 91.1 56.1 0.92 0.00
Ceftazidime 1.3 6.9 18.5 29.2 16.3 14.9 11.4 4.8 3.5 11.9 0.13 0.73
Ceftriaxone 1.6 2.9 7.1 8.4 10.6 16.2 13.8 17.3 25.9 11.5 0.96 0.00
Cefepime 11.3 4.9 6.3 5.2 1.9 6.5 12.8 15.3 21.9 9.5 0.64 0.07
Cefoxitin 0.7 2.8 3.5 1.5 6.1 8.8 18.1 21.0 20.0 9.2 0.93 0.00
Flomoxef 0.8 0.2 1.2 4.3 6.4 10.5 17.5 4.6 0.86 0.01
Cefuroxime 13.5 9.4 12.9 16.1 4.6 17.3 5.1 2.0 0.1 9.0 0.65 0.06
Carbapenems 4.9 6.5 7.2 13.0 14.6 19.7 42.5 49.4 44.1 22.4 0.93 0.00
Imipenem 2.3 4.7 4.9 11.2 12.4 16.9 7.7 5.7 4.8 7.8 0.24 0.54
Meropenem 2.6 1.8 2.2 1.9 2.3 2.8 13.9 7.2 1.5 4.0 0.41 0.28
Ertapenem 20.9 36.5 37.8 10.6 0.90 0.29
Quinolones 30.9 37.8 54.8 76.6 66.7 67.4 53.8 44.2 36.3 52.0 0.08 0.83
Ciprofloxacin 27.7 33.4 47.0 69.4 58.1 47.7 29.6 17.2 11.0 37.9 0.41 0.27
Levofloxacin 3.2 4.4 7.7 7.1 8.6 19.8 19.2 21.6 20.6 12.5 0.94 0.00
Penicillins
Ampicillin/sulbactam 13.7 38.1 68.9 92.5 117 76.9 80.3 48.9 30.0 62.9 0.15 0.71
Amoxicillin/clavulanic acid 6.0 4.7 11.5 14.8 26.7 35.2 42.7 56.9 22.1 0.97 0.00
Piperacillin 7.6 9.8 4.5 5.5 12.4 16.4 9.0 6.0 7.4 8.7 0.09 0.81
Piperacillin/tazobactam 1.1 2.8 4.2 8.7 15.6 23.6 24.4 33.5 39.5 17.0 0.98 0.00
Tigecycline 0.2 0.3 4.1 2.3 3.0 1.1 0.79 0.01
a Patient-days are only for patients from intensive care units, respiratory care ward, and general inpatients.
DDD Z defined daily dose.
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examples, use of extended-spectrum cephalosporins as
well as reduced use of aminoglycoside and first-generation
cephalosporins and development of related resistance in E.
coli; development of resistance to all five antimicrobial
groups used and reduced consumption of aminoglycosides
in K. pneumoniae; use of aminoglycosides, extended-
spectrum cephalosporins, and piperacillin/tazobactam to
develop resistance to these antimicrobial agents in P. aer-
uginosa; use of carbapenem and development of resistance
to imipenem and meropenem in A. baumannii (Table 4).Discussion
Antibiotic-resistant bacteria in humans have been related
to maternal and environmental microbial origins22 and can
transfer from animals to humans through consumption of
contaminated meats and other products. In this study, the
major antimicrobial agents, for which significant increases
in consumption were found, included extended-spectrum
cephalosporins and carbapenems, although aminoglyco-
side and first-generation cephalosporins consumption
significantly decreased (Table 2). The association of anti-
microbial consumption with the development of antimi-
crobial resistance has been reported to be dependent on
the species and antimicrobial agent. The aminoglycoside
consumption developed resistance to amikacin in K. pneu-
moniae and resistance to gentamicin in E. coli, resistanceto both antimicrobials in P. aeruginosa, no resistance to
both in A. baumannii and P. mirabilis (Table 4). These re-
sults also partially confirmed the report that aminoglyco-
side resistance was not associated with its consumption in
Gram-negative bacteria.23
Despite decreases in the consumption of fluo-
roquinolones, gentamicin and trimethoprim/sulfonamide,
the resistance to these agents increased in E. coli.24 Cip-
rofloxacin consumption could significantly increase the
resistance to ceftazidime in K. pneumoniae, resistance to
ceftazidime, ciprofloxacin or imipenem in A. baumannii
and resistance to imipenem, ceftazidime and ciprofloxacin
in P. aeruginosa.25 Consumption of antimicrobial agents to
develop resistance to other antimicrobial agents also
occurred in E. coli; for example: cephalosporin use and
nitrofurantoin resistance; amoxicillin use and fluo-
roquinolone resistance; and fluoroquinolone use and
ampicillin resistance.26
An increasing use of extended-spectrum cephalosporins
(particularly ceftazidime) could develop ceftazidime
resistance in K. pneumoniae, Enterobacter spp. and P.
aeruginosa in humans.27e31 Such correlation between
application of third- and fourth-generation cephalosporins
and increase of extended-spectrum cephalosporinase-pro-
ducing E. coli has been reported in pigs,32 implying that the
ESBL-producing E. coli can transfer from the contaminated
meat and products to humans. In the present study, cor-
relation between extended-spectrum cephalosporin use
and development of resistance to these antimicrobials were
Table 3 Trends of resistance rates among five Gram-negative pathogens from 2003 to 2011
Species Antimicrobial agent 2003 2004 2005 2006 2007 2008 2009 2010 2011 Mean r p
Escherichia
coli
Amikacin 7 8 10 15 10 18 18 9 11 11 0.35 0.36
Gentamicin 46 51 59 59 57 62 61 58 56 57 0.63 0.07
Ampicillin/sulbactam 42 46 56 57 69 79 80 72 79 65 0.93 0.00
Piperacillin/tazobactam 3 11 14 19 11.6 0.93 0.07
Cefazolin 31 38 53 51 64 71 72 70 (81)a 56 (59) 0.95 (0.96) 0.00
0.00
Cefoxitin 15 25 50 55 59 65 65 64 50 0.91 0.00
Ceftazidime 11 19 33 35 47 47 32 0.97 0.00
Ceftriaxone 21 28 40 53 61 61 61 (69) 46 (49) 0.96 (0.97) 0.00
Cefepime 3 4 11 22 27 40 31 24 17 20 0.63 0.07
Ciprofloxacin 29 36 49 55 58 62 71 52 0.98 0.00
Levofloxacin 35 51 70 65 65 57 0.92 0.03
Meropenem 0 0 0 0 0 0 0.2 (0) 0.03 (0.41) 0.00
(0.27)
Tigecycline 0 0 0
Klebsiella
pneumoniae
Amikacin 17 12 22 19 29 36 39 35 35 27 0.90 0.00
Gentamicin 40 35 42 53 59 62 62 51 52 51 0.67 0.05
Ampicillin/sulbactam 38 43 49 60 70 73 74 68 67 60 0.86 0.00
Piperacillin 45 33 93 98 67 0.90 0.01
Piperacillin/tazobactam 10 22 32 40 26 0.97 0.03
Cefazolin 40 38 47 61 69 69 70 67 (67) 58 (59) 0.90 (0.86) 0.00
Cefoxitin 33 23 57 64 66 63 50 51 0.78 0.04
Ceftazidime 13 16 25 43 41 47 31 0.96 0.00
Ceftriaxone 26 22 30 40 44 41 43 (40) 35 (36) 0.92 (0.86) 0.00
Cefepime 5 6 15 36 33 41 34 36 22 25 0.67 0.05
Ciprofloxacin 20 17 35 46 47 50 39 36 0.80 0.03
Levofloxacin 22 45 53 42 39 40 0.74 0.16
Meropenem 1 1.5 0.9 0 0.3 1.3 (0.5) 0.8 0.137 (0.04) 0.77
(0.93)
Tigecycline 0 0 0
Proteus
mirabilis
Amikacin 27 30 30 23 23 35 33 36 41 31 0.70 0.04
Gentamicin 74 77 83 81 90 80 81 84 82 81 0.49 0.18
Ampicillin/sulbactam 59 47 64 66 74 62 56 55 65 61 0.17 0.67
Cefazolin 65 67 80 81 80 76 78 75 (92) 75 (77) 0.54 (0.70) 0.17
(0.03)
Cefoxitin 0 0 50 d 49 42 33 38 38 31 0.60 0.12
Cefuroxime 37 41 38 30 30 31 35 0.80 0.06
Ceftazidime 10 14 12 12 14 10 12 0.00 1
Ceftriaxone 27 32 24 17 17 28 20 16 (35) 23 (24) 0.61
(0.09)
0.11
(0.83)
Cefepime 12 9 10 9 3 5 7 4 12 8 0.34 0.37
Pseudomonas
aeruginosa
Amikacin 22 20 15 11 13 10 9 14 6 13 0.84 0.00
Gentamicin 55 52 45 49 48 43 44 36 35 45 0.93 0.00
Piperacillin 14 12 12 20 22 16 d 24 29 19 0.87 0.01
Piperacillin/tazobactam 8 10 11 16 15 12 11 20 23 14 0.79 0.01
Ceftazidime 4 2 5 8 9 11 7 10 10 7 0.81 0.01
Cefepime 3 5 6 9 15 18 7 10 8 9 0.44 0.24
Ciprofloxacin 39 40 38 45 45 49 48 35 44 43 0.28 0.47
Levofloxacin 33 49 50 37 46 43 0.57 0.31
Imipenem 15 16 9 9 15 17 15 17 28 16 0.62 0.08
Meropenem d 16 16 15 15 18 15 26 29 19 0.76 0.03
Acinetobacter
baumannii
Amikacin 83 85 83 82 80 83 80 83 89 83 0.22 0.57
Gentamicin 95 91 93 93 95 95 88 92 95 93 0.13 0.74
Ampicillin/sulbactam 36 22 34 36 48 55 66 71 85 50 0.95 0.00
Piperacillin/tazobactam 82 89 87 93 d 80 86 0.18 0.77
Ceftazidime 85 89 87 90 95 86 89 0.39 0.45
Cefepime 83 86 83 88 87 93 88 85 89 87 0.53 0.14
(continued on next page)
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Table 3 (continued )
Species Antimicrobial agent 2003 2004 2005 2006 2007 2008 2009 2010 2011 Mean r p
Ciprofloxacin 83 83 84 88 89 94 97 88 0.96 0.00
Levofloxacin 81 90 88 84 87 86 0.62 0.27
Imipenem 3 8 6 22 25 40 77 26 0.91 0.01
Meropenem 2 15 32 53 52 69 78 90 49 0.99 0.00
Tigecycline 9 6 7.5
a Resistance rates in parentheses were determined by 2010 Clinical and Laboratory Standards Institute (CLSI) guideline and others
were determined by 2003e2009 CLSI guideline. Resistance criteria in Enterobacteriaceae between 2003 and 2009 and 2010 CLSI
guidelines changed from 14 mm to 19 mm for cefazolin, from 13 mm to 19 mm for ceftriaxone, from 15 mm to 19 for erta-
penem, from 13 mm to 19 mm for imipenem and from 13 mm to 19 mm for meropenem.
652 H.-S. Lee et al.only observed in P. aeruginosa, E. coli, and K. pneumoniae,
not in P. mirabilis and A. baumanii (Table 4).
Because of the dissemination and spread of ESBL-
producing bacteria, carbapenem has been replaced
extended-spectrum cephalosporins as therapeutic drugs
for the bacterial infection. In Germany, an increase in
third-generation cephalosporin-resistant E. coli and K.
pneumoniae was accompanied by a twofold increase in
carbapenem consumption and then increased carbape-
nem resistance in K. pneumoniae and A. baumannii.33 In
the present study, a significant correlation between
carbapenem consumption and resistance to these agents
was also observed in K. pneumoniae and A. baumannii
(Table 4). In Taiwan, CRAB was found to be, on average,
46% in hospitals20 and has increased meropenem resis-
tance to 48.4%.34 Our data demonstrated a higher
resistance to meropenem and imipenem in A. bau-
mannii, with a prevalence of 69% and 77%, respectively.
This higher CRAB rate is possibly because the patients
are mainly veterans with an average age of 66 years in
the nursing home of our hospital. Additionally, the
gradually increasing consumption of piperacillin/tazo-
bactam for treatment was correlated with an increase in
piperacillin/tazobactam resistance in K. pneumoniae and
P. aeruginosa (Table 4).Table 4 Relationship between annual antimicrobial agent consu
Antimicrobial agent group Species
Aminoglycosides Klebsiella pneumoniae
Escherichia coli
Pseudomonas aerugino
First-generation cephalosporins E. coli
Extended-spectrum cephalosporins K. pneumoniae
E. coli
P. aeruginosa
Carbapenems K. pneumoniae
Acinetobacter bauman
A. baumannii
Quinolone K. pneumoniae
Piperacillin/tazobactam K. pneumoniae
P. aeruginosaTo inhibit the development of antimicrobial resistance
due to antimicrobial agent-inducing mutations, the lowest
concentration (mutant prevention concentration, MPC)
that prevents the growth of resistant colonies is commonly
used. Therefore, an antimicrobial concentration above MPC
during therapy can inhibit mutant subpopulation amplifi-
cation.35 An analysis of MPC for E. coli ATCC 25922 varied
from 2  minimal inhibitory concentration (MIC) for trova-
floxacin, 4  MIC for ciprofloxacin, norfloxacin and oflox-
acin, 8  MIC for clinafloxacin and levofloxacin, 16  MIC
for sparfloxacin and 32  MIC for nalidixic acid at 37C
under aerobic conditions.34 The MPC/MIC value of urinary
tract infection E. coli was 16 for ciprofloxacin resistance
(4 mg/L) and up to 5 for ciprofloxacin susceptibility (1 mg/
L).36 Furthermore, P. aeruginosa showed significant corre-
lation between ciprofloxacin use and its resistance devel-
opment.35 In our study, the decrease in quinolone
consumption since 2006 was associated with an increase in
its resistance in A. baumannii, E. coli, K. pneumoniae, and
P. aeruginosa, possibly due to the increasing levofloxacin
consumption (Table 2). The ciprofloxacin MPC was two-fold
lower than that of levofloxacin; therefore, the increased
use of levofloxacin possibly induced bacterial resistance. In
an effort to reduce antimicrobial-resistant bacteria, the
extensive implementation of antimicrobial stewardship hasmption and antimicrobial resistance in four bacterial species
Resistance to r p
Amikacin 0.970 0.000
Gentamicin 0.796 0.001
sa Amikacin 0.836 0.005
Gentamicin 0.776 0.014
Cefazolin 0.880 0.004
Ceftazidime 0.858 0.029
Ceftriaxone 0.869 0.011
Ceftriaxone 0.900 0.006
Cefazolin 0.845 0.008
Ceftazidime 0.792 0.019
Imipenem 0.936 0.002
nii Imipenem 0.993 0.000
Meropenem 0.886 0.008
Ciprofloxacin 0.934 0.002
Piperacillin/tazobactam 0.958 0.042
0.792 0.011
Antimicrobial use and resistance development 653significantly decreased the consumption of second-
generation cephalosporins, carbapenems, and aminoglyco-
side and reduced the appearance of methicillin-resistant
Staphylococcus aureus and antimicrobial-resistant Serra-
tia marcescens.37 Therefore, a effective implementation of
antimicrobial use and MPC are needed to reduce the
development of antimicrobial resistance.
In Enterobacteriaceae, K. pneumoniae developed resis-
tance to all antimicrobial groups most easily, followed by E.
coli. This higher resistance may be due to the thick poly-
saccharide capsule in general around K. pneumoniae. No
correlation between antimicrobial consumption and its
resistance was observed in P. mirabilis, which is frequently
considered to be contamination. However, MDR P. mirabilis
is commonly identified in this hospital. P. aeruginosa
developed resistance to b-lactam antimicrobials and ami-
noglycosides, while A. baumanii only developed resistance
to carbapenems associated with their use.
Conflicts of interest
All contributing authors declare no conflicts of interest.
Acknowledgments
This work was funded by grants from Chiayi Branch, Tai-
chung Veterans Hospital RVHCY99004 and RVHCY100002 and
the National Scicence council NSC98-2321-B-415-003, Ex-
ecutive Yuan, Taiwan, ROC.
References
1. Solomon S, Horan T, Andrus M, Edwards J, Fridkin S, Koganti J,
et al. National Nosocomial Infections Surveillance (NNIS) system
report, data summary from January 1992 through June 2003,
issued August 2003. Am J Infect Control 2003;31:481e98.
2. Eveillard M, Schmit JL, Eb F. Antimicrobial use prior to the
acquisition of multiresistant bacteria. Infect Control Hosp
Epidemiol 2002;23:155e8.
3. Livermore DM. Bacterial resistance. Origins, epidemiology, and
impact. Clin Infect Dis 2003;36(Suppl. 1):S11e23.
4. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria.
Drugs 2004;64:159e204.
5. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance
on health and economic outcomes. Clin Infect Dis 2003;36:
1433e7.
6. Buke C, Armand-Lefevre L, Lolom I, Guerinot W, Deblangy C,
Ruimy R, et al. Epidemiology of multidrug-resistant bacteria in
patients with long hospital stays. Infect Control Hosp Epi-
demiol 2007;28:1255e60.
7. Gales AC, Jones RN, Andrade SS, Sader HS. Antimicrobial sus-
ceptibility patterns of unusual nonfermentative Gram-negative
bacilli isolated from Latin America: report from the SENTRY
Antimicrobial Surveillance Program (1997-2002). Mem Inst
Oswaldo Cruz 2005;100:571e7.
8. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical
and economic impact of multidrug resistance in nosocomial
Acinetobacter baumannii bacteremia. Infect Control Hosp
Epidemiol 2007;28:713e9.
9. Jacoby TS, Kuchenbecker RS, Dos Santos RP, Magedana L,
Guzatto P, Moreira LB. Impact of hospital-wide infection rate,
invasive procedures use and antimicrobial consumption onbacterial resistance inside an intensive care unit. J Hosp Infect
2010;75:23e7.
10. Hsueh PR, Snyder TA, Dinubile MJ, Satischandran V,
McCarroll K, Chow JW, et al. In vitro susceptibilities of aerobic
and facultative Gram-negative bacilli isolated from patients
with intra-abdominal infection in the AsiaePacific region. 2004
results from SMART (Study for Monitoring Antimicrobial Resis-
tance Trends). Int J Antimicrob Agents 2006;28:238e43.
11. Karlowsky JA, Jones ME, Thornsberry C, Friedland IR, Sahm DF.
Trends in antimicrobial susceptibilities among Enter-
obacteriaceae isolated from hospitalized patients in the
United States from 1998 to 2001. Antimicrob Agents Chemo-
ther 2003;47:1672e80.
12. Jean SS, Hsueh PR. Antimicrobial drug resistance in Taiwan. J
Formas Med Assoc 2011;110:4e13.
13. Lo WT, Lin WJ, Chiueh TS, Lee SY, Wang CC, Lu JJ. Changing
trends in antimicrobial resistance of major bacterial patho-
gens, 1985e2005: a study from a medical center in northern
Taiwan. J Microbial Immunol Infect 2011;44:131e8.
14. Ziha-Zarifi I, Llanes C, Ko¨hler T, Pechere JC, Plesiat P. In vivo
emergence of multidrug-resistant mutants of Pseudomonas
aeruginosa overexpressing the active efflux system MexA-
MexB-OprM. Antimicrob Agents Chemother 1999;43:287e91.
15. Oh H, Stenhoff J, Jalal S, Wretlind B. Role of efflux pumps and
mutations in genes for topoisomerases II and IV in
fluoroquinolone-resistant Pseudomonas aeruginosa strains.
Microb Drug Resist 2003;9:323e8.
16. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et al.
Pandrug-resistant Acinetobacter baumannii causing nosoco-
mial infections in a university hospital, Taiwan. Emerg Infect
Dis 2002;8:827e32.
17. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S,
Maurer J, et al. Class restriction of cephalosporin use to con-
trol total cephalosporin resistance in nosocomial Klebsiella.
JAMA 1998;280:1233e7.
18. Corbella X, Montero A, Pujol M, Domı´nguez MA, Ayats J,
Argerich MJ, et al. Emergence and rapid spread of carbapenem
resistance during a large and sustained hospital outbreak of
multiresistant Acinetobacter baumannii. J Clin Microbiol 2000;
38:4086e95.
19. Lee SO, Kim NJ, Choi SH, Hyong Kim T, Chung JW, Woo JH,
et al. Risk factors for acquisition of imipenem-resistant Aci-
netobacter baumannii: a case-control study. Antimicrob
Agents Chemother 2004;48:224e8.
20. Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, et al.
Increase of carbapenem-resistant Acinetobacter baumannii
infection in acute care hospitals in Taiwan: association with
hospital antimicrobial usage. PLoS ONE 2012;7:e37788.
21. CLSI. Performance standards for antimicrobial disk suscepti-
bility. Approved standard 10th M02eA10. Clinical and Labo-
ratory Standards Institute, Villanova, PA; 2010.
22. Zhang L, Kinkelaar D, Huang Y, Li Y, Li X, Wang HH. Acquired
antibiotic resistance: are we born with it? Appl Environ
Microbiol 2011;77:7134e41.
23. Hsueh PR, Chen WH, Luh KT. Relationships between antimi-
crobial use and antimicrobial resistance in Gram-negative
bacteria causing nosocomial infections from 1991e2003 at a
university hospital in Taiwan. Int J Antimicrob 2005;26:
463e72.
24. Kronvall G. Antimicrobial resistance 1979e2009 at Karolinska
hospital, Sweden: normalized resistance interpretation during
a 30-year follow-up on Staphylococcus aureus and Escherichia
coli resistance development. APMIS 2010;118:621e39.
25. Marcusson LL, Olofsson SK, Komp Lindgren P, Cars O, Hughes D.
Mutant prevention concentrations of ciprofloxacin for urinary
tract infection isolates of Escherichia coli. J Antimicrob Che-
mother 2005;55:938e43.
654 H.-S. Lee et al.26. Thabet L, Memmi M, Turki A, Messadi AA. The impact of fluo-
roquinolones use on antibiotic resistance in an intensive care
burn department. Tunis Med 2010;88:297e300.
27. Gentry C, Flournoy DJ, Reinert R. Analysis of antimicrobial
resistance among Gram-negative bacilli and antimicrobial use
in intensive care unit patients for 5 years in a Veterans Affairs
medical center. Am J Infect Control 2002;30:411e6.
28. Bantar C, Vesco E, Heft C, Salamone F, Krayeski M, Gomez H,
et al. Replacement of broad-spectrum cephalosporins by
piperacillinetazobactam: impact on sustained high rates of
bacterial resistance. Antimicrob Agents Chemother 2004;48:
392e5.
29. Lesch CA, Itokazu GS, Danziger LH, Weinstein RA. Multi-hos-
pital analysis of antimicrobial usage and resistance trends.
Diagn Microbiol Infect Dis 2001;41:149e54.
30. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH,
Karam G, Quinn JP. Antibiotic resistance among gram-negative
bacilli in US intensive care units: implications for fluo-
roquinolone use. JAMA 2003;289:885e8.
31. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Cefatizidime-
resistant Klebsiella pneumoniae isolates recovered at the
Cleveland Department of Veterans Affairs Medical Center. Clin
Infect Dis 1996;23:118e24.
32. Agersø Y, Aarestrup FM, Pedersen K, Seyfarth AM, Struve T,
Hasman H. Prevalence of extended-spectrum cephalosporinase(ESC)-producing Escherichia coli in Danish slaughter pigs and
retail meat identified by selective enrichment and association
with cephalosporin usage. J Antimicrob Chemother 2012;67:
582e8.
33. Meyer E, Schwab F, Schroeren-Boersch B. Gastmeier. Dramatic
increase of third-generation cephalosporin-resistant E. coli in
German intensive care units: secular trends in antibiotic drug
use and bacterial resistance, 2001 to 2008. Critical Care 2010;
14:R113.
34. Lai CC, Wang CY, Chu CC, Tan CK, Lu CL, Lee YC, et al. Cor-
relation between antibiotic consumption and resistance of
Gram-negative bacteria causing healthcare-associated in-
fections at a university hospital in Taiwan from 2000 to 2009.
J Antimicrob Chemother 2011;66:1374e82.
35. Zhao X, Drlica K. A unified anti-mutant dosing strategy.
J Antimicrob Chemother 2008;62:434e6.
36. Bergman M, Nyberg ST, Huovinen P, Paakkari P, Hakanen AJ.
Finnish Study Group for Antimicrobial Resistance. Association
between antimicrobial consumption and resistance in Escher-
ichia coli. Antimicrob Agents Chemother 2009;53:912e7.
37. Niwa T, Shinoda Y, Suzuki A, Ohmori T, Yasuda M, Ohta H, et al.
Outcome measurement of extensive implementation of anti-
microbial stewardship in patients receiving intravenous anti-
biotics in a Japanese university hospital. Int J Clin Pract 2012;
66:999e1008.
